RxDoctor Payments Data

Setare Eslami, MD

Psychiatry · Bakersfield, CANPI 1508399122

Payments from drug & device makers

$2,279in general payments, 2019–2025

Across 94 payments — averaging $24.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$742
  • Otsuka America Pharmaceutical, Inc.$367
  • Alkermes, Inc.$301
  • Lundbeck LLC$152
  • Johnson & Johnson$122
  • Axsome Therapeutics, Inc.$104
  • plus $491 from 9 others

What the payments were for

  • Food & beverage$2,20197%
  • Education$783%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,279 in reported general payments places this provider in the 80th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$75,878
Medicare patients
128
Services billed
890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate25$216,869
RexultiBrexpiprazole11$23,773
TrintellixVortioxetine Hydrobromide22$19,508
SuboxoneBuprenorphine Hcl/Naloxone Hcl25$12,385
Paliperidone ErPaliperidone12$2,056
Desvenlafaxine Succinate ErDesvenlafaxine Succinate42$1,706
Venlafaxine Hcl ErVenlafaxine Hcl32$1,552
Chlorpromazine Hcl17$1,443
Aripiprazole34$1,358
Buspirone Hcl84$1,197
Bupropion XlBupropion Hcl73$1,190
Trazodone Hcl88$1,114
Quetiapine Fumarate48$1,095
Duloxetine Hcl58$818
Divalproex Sodium ErDivalproex Sodium18$616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$367$23,77311 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$90$19,50822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →